Literature DB >> 30312380

Prevention of Pneumococcal Infections in Adults Using Conjugate Vaccines: No Easy Answers.

Daniel M Weinberger1, Eugene D Shapiro1,2.   

Abstract

Keywords:  adult vaccination; conjugate vaccines; pneumococcus; streptococcus pneumoniae; vaccines

Year:  2019        PMID: 30312380      PMCID: PMC6579952          DOI: 10.1093/cid/ciy873

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.

Authors:  Shamez N Ladhani; Sarah Collins; Abdelmajid Djennad; Carmen L Sheppard; Ray Borrow; Norman K Fry; Nicholas J Andrews; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet Infect Dis       Date:  2018-01-26       Impact factor: 25.071

2.  Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.

Authors:  Lone Simonsen; Robert J Taylor; Cynthia Schuck-Paim; Roger Lustig; Michael Haber; Keith P Klugman
Journal:  Lancet Respir Med       Date:  2014-03-10       Impact factor: 30.700

3.  Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades.

Authors:  Zitta B Harboe; Thomas L Benfield; Palle Valentiner-Branth; Thomas Hjuler; Lotte Lambertsen; Margit Kaltoft; Karen Krogfelt; Hans Christian Slotved; Jens Jørgen Christensen; Helle B Konradsen
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

4.  The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.

Authors:  Stefan Flasche; Olivier Le Polain de Waroux; Katherine L O'Brien; W John Edmunds
Journal:  PLoS Comput Biol       Date:  2015-04-16       Impact factor: 4.475

Review 5.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia.

Authors:  Jennifer D Loo; Laura Conklin; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 6.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage.

Authors:  Katherine E Fleming-Dutra; Laura Conklin; Jennifer D Loo; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 7.  Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.

Authors:  Jennifer D Loo; Laura Conklin; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; Jennifer Kirk; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

8.  Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Authors:  Daniel R Feikin; Eunice W Kagucia; Jennifer D Loo; Ruth Link-Gelles; Milo A Puhan; Thomas Cherian; Orin S Levine; Cynthia G Whitney; Katherine L O'Brien; Matthew R Moore
Journal:  PLoS Med       Date:  2013-09-24       Impact factor: 11.069

  8 in total
  2 in total

Review 1.  Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections.

Authors:  Charles Feldman; Ronald Anderson
Journal:  F1000Res       Date:  2020-05-07

2.  Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.

Authors:  Hye-Young Kim; Seong-Beom Park; Eun-Sil Kang; Sang-Min Lee; Hyun-Jin Kim; Matt Wasserman
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.